Many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin. But some people with moderate or severe plaque psoriasis have symptoms that do ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Several classification systems, all based on disease severity, have been created to guide treatment decisions in psoriasis. In the most widely used system, disease severity is scored according to the ...

Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...

ATLANTA, Sept. 17, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Please provide your email address to receive an email when new articles are posted on . Otezla is now available in the U.S. to treat children and adolescents with moderate to severe plaque psoriasis.

Dec. 16, 2003 — Efalizumab improves clinical end points for patients with severe plaque psoriasis, according to the results of a phase III, double-blind trial published in the Dec. 17 issue of The ...

Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis. Amgen has announced the availability of apremilast (Otezla) in the United ...

Uveitis severity is often worse, bilateral, and prolonged among individuals with chronic plaque psoriasis. Uveitis severity is worse and tends to be bilateral and prolonged in individuals with chronic ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...